However, owing to the higher risk of ADRs in the C25 group, and considering the results of the PROSELICA and TROPIC studies, we suggest that clinicians should carefully assess the risk of clinically significant ADRs, such as neutropenia and febrile neutropenia, and the possibility of prophylactic G-CSF when selecting the starting dose of cabazitaxel for patients with CRPC. This evidence concerns the gene CSF3 and Decreased total neutrophil count.